Fierce Pharma

SEPTEMBER 10, 2024

After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. | Late Monday, the U.S. House of Representatives voted 306-81 in favor of the BIOSECURE Act, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies: WuXi AppTec, WuXi Biologics, BGI Group, MGI and Complete Genomics.

327

327

MedCity News

SEPTEMBER 10, 2024

Some of the most difficult processes for digital health startups to navigate are those related to reimbursement and coding. Startups will often need to create entirely new codes for their products, so they should start thinking about this sooner rather than later, experts said at a recent conference. The post Why Digital Health Startups Should Start Thinking About Their Reimbursement Pathway Earlier appeared first on MedCity News.

123

123

Fierce Pharma

SEPTEMBER 10, 2024

Eleven months after sustaining a rejection from the FDA for Dupixent to treat c | Eleven months after sustaining a rejection from the FDA for Dupixent to treat chronic spontaneous urticaria, Sanofi and Regeneron have presented data from a phase 3 trial that could help push the megablockbuster across the finish line in the indication.

FDA 147

FDA 147

MedCity News

SEPTEMBER 10, 2024

A CEO and father of two reflects on the Surgeon General’s recent advisory, evolving pressures on today’s parents and the impact on mental health. The post Parenting: The New Mental Health Threat? appeared first on MedCity News.

Management 115

Management Patients 115

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

SEPTEMBER 10, 2024

In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special | In this week's episode of "The Top Line," we will dive into the annual Fierce 50 special report.

Specialization 130

Specialization 130

MedCity News

SEPTEMBER 10, 2024

Roivant Sciences subsidiary Pulmovant is on track for a Phase 2 test of mosliciguat as a treatment for pulmonary hypertension associated with interstitial lung disease. The inhaled drug offers a different mechanism of action and less burdensome dosing compared to United Therapeutics’ blockbuster PH-ILD drug, Tyvaso. The post Bayer Asset Gives Roivant Sciences’ New ‘Vant’ a Shot at Besting a United Therapeutics Lung Drug appeared first on MedCity News.

Biopharma 110

Biopharma Pharma 110

Pharmaceutical Commerce

SEPTEMBER 10, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

MedCity News

SEPTEMBER 10, 2024

Adding generative AI and other AI tools to coding and chart review practices streamlines a complex process and better positions plans for risk adjustment audits. The post Medicare Advantage Audit Ready with AI appeared first on MedCity News.

105

105

Pharmaceutical Commerce

SEPTEMBER 10, 2024

A pooled analysis of the SWIFT-1 and SWIFT-2 trials found 54% reduction in exacerbation rates over 52 weeks in patients with severe asthma with type 2 inflammation treated with depemokimab.

Patients 105

Patients 105

PharmaTimes

SEPTEMBER 10, 2024

Critically ill individuals will benefit from futuristic tech

Medicine 101

Medicine Patients 101

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

PharmaVoice

SEPTEMBER 10, 2024

Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.

Medicine 98

Medicine Pharmaceutical 98

PharmaTimes

SEPTEMBER 10, 2024

Molecular imaging agent 99mTc-maraciclatide to aid in disease prognostication

93

93

pharmaphorum

SEPTEMBER 10, 2024

Bayer and Boehringer present data on competing oral HER2 drugs at WCLC, as they run phase 3 trials in NSCLC with HER2 activations.

72

72

Pharmaceutical Technology

SEPTEMBER 10, 2024

Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall survival than chemotherapy.

Patients 59

Patients 59

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

SEPTEMBER 10, 2024

Terns Pharma files $125m+ public offering to support trials of its oral GLP-1 agonist candidate TERN-601 for obesity.

Pharma 64

Pharma 64

European Pharmaceutical Review

SEPTEMBER 10, 2024

Results from GSK’s two Phase III clinical trials evaluating the biologic depemokimab has shown promise in extending dosing intervals in severe asthma, with individuals just requiring two doses annually. The injectable treatment was assessed against placebo in the SWIFT-1 and SWIFT-2 trials and open label extension study (AGILE). It is the first ultra-long-acting biologic to be evaluated in Phase III trials.

Medicine 59

Medicine Pharmaceutical Patients 59

Pharmaceutical Technology

SEPTEMBER 10, 2024

The US House of Representatives has passed a bill to restrict business with certain Chinese biotech companies.

59

59

pharmaphorum

SEPTEMBER 10, 2024

GSK's long-acting drug antibody for severe asthma, depemokimab, cut the rate of attacks by 54% in phase 3 trials presented at ERS.

59

59

Advertisement

Pharmacy Times

SEPTEMBER 10, 2024

To help with treatment response and compliance as well as optimize treatment, communication between patients and health care providers is necessary.

Patients 59

Patients 59

pharmaphorum

SEPTEMBER 10, 2024

Researchers have shown that COPD exacerbations can be predicted by looking for vocal biomarkers in recorded speech

59

59

Pharmacy Times

SEPTEMBER 10, 2024

When IVIG was administered within 48 hours of hospital admission, hospital and ICU length of stay were dramatically shortened.

Patients 52

Patients 52

PharmaTech

SEPTEMBER 10, 2024

Susan J. Schniepp, member of the editorial advisory boards for Pharmaceutical Technology, Pharmaceutical Technology EuropeT, and BioPharm International, provides an update on her experience working in the pharmaceutical industry and what she sees for the industry’s future.

Pharmaceutical 52

Pharmaceutical 52

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

52

52

PharmExec

SEPTEMBER 10, 2024

Results from the Phase Ib Beamion LUNG-1 trial found that zongertinib achieved an objective response rate of 66.7% in previously treated patients with advanced non-small cell lung cancer with HER2 mutations.

Patients 52

Patients 52

Pharmaceutical Technology

SEPTEMBER 10, 2024

The new biotech has inherited two T cell engager antibodies as part of a three-way merger with Vignette and TRC 2004.

52

52

PharmExec

SEPTEMBER 10, 2024

In this interview, Melissa Krebs, CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.

Marketing 52

Marketing 52

Advertisement

Distribution

Pharmaceutical Technology

SEPTEMBER 10, 2024

Data from the two Phase III trials showed that efsitora induced HbA1C reductions similar to daily insulin in both type 1 and 2 diabetes.

52

52

Pharmaceutical Commerce

SEPTEMBER 10, 2024

The company boosts its healthcare logistics services by agreeing to purchase Frigo-Trans and its sister company BPL.

Healthcare 52

Healthcare Healthcare 52

PharmaTech

SEPTEMBER 10, 2024

The 2024 CPHI Pharma Awards comprise finalists spanning 14 categories and includes awards for future leaders, women of the year, and an “at the heart of pharma” category.

Pharma 52

Pharma 52

Pharmaceutical Technology

SEPTEMBER 10, 2024

The study involved over 3,600 participants, including FDRs of newly diagnosed type 1 diabetes patients in Denmark and children in Sweden.

Patients 52

Patients 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales